Lv1
48 积分 2025-03-13 加入
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
18天前
已完结
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
9个月前
已完结
Anti-Nephrin Antibodies in Adult Chinese Patients with Minimal Change Disease and Primary Focal Segmental Glomerulosclerosis
9个月前
已完结
The efficacy and safety of rituximab in adult patients with steroid-dependent or frequent relapsing nephrotic syndrome: A retrospective study
9个月前
已完结
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy
10个月前
已完结
What Are Baskets, Umbrellas, and Platforms Doing in Nephrology Clinical Trials?
11个月前
已关闭
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1年前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1年前
已完结
Rituximab, tacrolimus, cyclophosphamide and cyclosporin in primary membranous nephropathy with nephrotic syndrome: comparison of safety profiles, effect on remission rate, 24-h urinary total protein, serum albumin, and serum creatinine levels using network meta-analysis
1年前
已完结
皖公网安备34019202002308
